Delcath Systems (NASDAQ:DCTH) Trading 1.7% Higher

Delcath Systems, Inc. (NASDAQ:DCTH) shares rose 1.7% on Wednesday . The company traded as high as $8.89 and last traded at $8.84. Approximately 173,348 shares changed hands during mid-day trading, a decline of 29% from the average daily volume of 243,169 shares. The stock had previously closed at $8.69.

Wall Street Analyst Weigh In

A number of brokerages recently commented on DCTH. Craig Hallum assumed coverage on shares of Delcath Systems in a research note on Friday, June 28th. They set a “buy” rating and a $18.00 target price for the company. Stephens initiated coverage on Delcath Systems in a report on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 price objective on the stock. HC Wainwright boosted their target price on Delcath Systems from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, May 15th. Finally, StockNews.com raised Delcath Systems to a “sell” rating in a report on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat, Delcath Systems presently has an average rating of “Moderate Buy” and an average price target of $19.83.

Delcath Systems Price Performance

The firm has a market cap of $245.66 million, a price-to-earnings ratio of -3.34 and a beta of 0.64. The stock has a 50-day moving average price of $7.71 and a 200 day moving average price of $5.73.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.43) EPS for the quarter, hitting the consensus estimate of ($0.43). Delcath Systems had a negative return on equity of 290.07% and a negative net margin of 1,080.72%. The company had revenue of $3.14 million for the quarter, compared to analyst estimates of $3.70 million. As a group, equities research analysts predict that Delcath Systems, Inc. will post -1.31 earnings per share for the current year.

Hedge Funds Weigh In On Delcath Systems

A number of institutional investors have recently modified their holdings of DCTH. AIGH Capital Management LLC purchased a new position in Delcath Systems during the 4th quarter worth $4,918,000. ADAR1 Capital Management LLC purchased a new position in shares of Delcath Systems during the fourth quarter worth about $962,000. Worth Venture Partners LLC acquired a new position in Delcath Systems in the 4th quarter valued at about $1,224,000. Vivo Capital LLC raised its stake in Delcath Systems by 94.9% during the 1st quarter. Vivo Capital LLC now owns 1,666,746 shares of the company’s stock valued at $7,950,000 after acquiring an additional 811,555 shares during the last quarter. Finally, Levin Capital Strategies L.P. lifted its position in Delcath Systems by 22.5% during the 4th quarter. Levin Capital Strategies L.P. now owns 49,000 shares of the company’s stock worth $204,000 after acquiring an additional 9,000 shares during the period. 61.12% of the stock is owned by institutional investors and hedge funds.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.